Advertisement

Mediastinal-, Lungen- und Pleuratumoren

  • A. Schalhorn
  • R. M. Huber

Zusammenfassung

Bei den Tumoren im Lungenbereich — mit Pleura und Mediastinum — ist nach wie vor in erster Linie das Bronchialkarzinom zu nennen. Bei Männern ist es der häufigste bösartige Tumor, bei Frauen bereits der dritthäufigste. In den letzten Jahren ist insbesondere die Chemotherapie durch die Entwicklung neuer Substanzen effektiver geworden/wie in neueren Studien gezeigt werden konnte (Anderson et al.2000; Rodriguez et al. 2001; Schalhorn 2002).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson H, Hopwood P, Stephens RJ et al. (2000) Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer — a randomized trial with quality of life as the primary outcome. Br J Cancer 83:447–453PubMedCrossRefGoogle Scholar
  2. Antman KH, Pass HI, Schiff PB (2001) Management of mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer — principles an practice of oncology, 6th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 1943–1969.Google Scholar
  3. Ardizzoni A, Hansen H, Dombernowsky P et al. (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090–2096PubMedGoogle Scholar
  4. Auperin A, Arriagada R, Pignon JP et al. (1999) Prophylactic cranial irradiation for patients with small-ceil lung cancer in complete remission. New Engl J Med 341:476–484PubMedCrossRefGoogle Scholar
  5. Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland, 3. Aufl.Springer, Berlin Heidelberg NewYorkTokyoGoogle Scholar
  6. Bonomi P, Kim KM, Fairclough D et al. (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin vs. etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 18:623–631PubMedGoogle Scholar
  7. Busch M, Lindner H, Zimmermann F (2000) Strahlentherapie. In: Schalhorn A (Hrsg) Tumorzentrum München: Empfehlungen zur Diagnostik, Therapie und Nachsorge -Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München, S 52–60Google Scholar
  8. Byrne MJ, Davidson JA, Musk AW et al. (1999) Cisplatin and gem-citabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17:25–30PubMedGoogle Scholar
  9. Calvert AH, Newell DR, Gumbrel JLA et al.(1989) Carboplatin dosage: a prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMedGoogle Scholar
  10. Cameron RB, Loehrer PJ, Thomas CR Jr (2001) Neoplasma of the mediastinum. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Cancer — principles an practice of oncology, 6th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 1019–1036Google Scholar
  11. Carbone DP (1997) The biology of lung cancer. Semin Oncol 24: 38–401Google Scholar
  12. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM (1988) Mitomycin, ifosfamide, and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58:359–361PubMedCrossRefGoogle Scholar
  13. Cullen MH, Billingham LJ, Woodroffe CM et al. (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life. J Clin Oncol 17: 3188–3194PubMedGoogle Scholar
  14. Depierre A, Chastang C, Quiox E et al. (1994) Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5:37–42PubMedGoogle Scholar
  15. Drings P, Bülzebruck H, Hruska D et al. (1986) EPICO in der Chemotherapie des kleinzelligen Bronchialkarzinoms. Fortschritte in der Chemotherapie. Aktuelle Onkol 29:104–114Google Scholar
  16. Fornasiero A, Daniele O, Sperandio P et al. (1985) Chemotherapy of invasive or metastatic thymoma: report of 11 cases. Cancer Treat Rep 68:1205–1210Google Scholar
  17. Gerl A, Clemm C, Kohl P et al. (1994) Primär extragonadale Keimzelltumoren. Med Klinik 89:240–244Google Scholar
  18. Göldel N, Böning L, Fredrik A et al. (1989) Chemotherapy of invasive thymoma. A retrospective study of 22 cases. Cancer 63: 1493–1500PubMedCrossRefGoogle Scholar
  19. Häußinger KE, Kohlhäufel E (2000) Ätiologie und Epidemiologie des Bronchialkarzinoms. In: Schalhorn A (Hrsg) Tumorzentrum München — Empfehlungen zur Diagnostik, Therapie und Nach-sorge:Tumoren der Lunge und des Mediastinums.Zuckschwerdt, München, S 1–4Google Scholar
  20. Hautmann H, Busch M, Fischer R et al. (2000) Palliative Therapie. In: Schalhorn A (Hrsg) Tumorzentrum München: Empfehlungen zur Diagnostik, Therapie und Nachsorge -Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München, S 91–104Google Scholar
  21. Huber M, Schalhorn A (2000) Multimodale Therapie des Bronchialkarzinoms. In: Schalhorn A (Hrsg) Tumorzentrum München: Empfehlungen zur Diagnostik, Therapie und Nachsorge: Tumoren der Lunge und des Mediastinums, Zuckschwerdt, München, S 82–87Google Scholar
  22. Huber R, Gatzemeier U, Gosse H et al. (2000) Topotecan as second line treatment of small cell lung cancer. Onkologie 23 (Suppl 3): 9–12CrossRefGoogle Scholar
  23. Huisman C, Smit EF, Giaccone G, Postmus PE (2000) Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 18:3722–3730PubMedGoogle Scholar
  24. Klastersky J, Sculier JP, Dumont IP et al. (1985) Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung.Cancer 56:71–75PubMedCrossRefGoogle Scholar
  25. Livingston RB (1980) Small cell carcinoma of the lung. Blood 56:575–584PubMedGoogle Scholar
  26. Livingston RB (1988) Treatment of advanced non-small cell lung cancer; the Southwest Oncology Group Experience. Semin Oncol 15 (Suppl 7):37–41PubMedGoogle Scholar
  27. Longeval E, De Jager R, Tatgnon H et al. (1980) Cisplatin-Vp 16–213 combination chemotherapy in non small cell bronchogenic carcinoma; phase I–II clinical trial. Proc AACR & ASCO 21: 368(C-195)Google Scholar
  28. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485–2492PubMedCrossRefGoogle Scholar
  29. Mezger J (2000) Benigne und maligne Mesotheliome. In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie, 2. Aufl.Thieme, Stuttgarts 738–742Google Scholar
  30. Natale R, Hilaris B, Goldbey R, Wittes R (1979) Induction chemotherapy in small cell carcinoma of the lung (SCCL). Proc AACR & ASCO 20: 343(C-214)Google Scholar
  31. Nathrath W, Müller A, Müller-Höcker J (2000) Tumoren des Mediastinums. Pathologie. In: Schalhorn A (Hrsg) Tumorzentrum München — Empfehlungen zur Diagnostik, Therapie und Nachsorge:Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München, S 114–120Google Scholar
  32. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  33. Parra H (2002) Superiority of three-week versus four-week schedule of cisplatin and gemcitabine.Results of a randomized phase II study. World Conference on Lung Cancer 2000:155Google Scholar
  34. Passlick B, Müller C, Thetter O (2000) Videoassisitierte thorakoskopis-che Chirurgie/minimal invasive Chirurgie. In: Schalhorn A (Hrsg) Tumorzentrum München: Empfehlungen zur Diagnostik, Therapie und Nachsorge -Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München, S 18–19Google Scholar
  35. Pawel J von, Schiller JH, Shepherd FA et al. (1999) Topotecan vs. cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667Google Scholar
  36. PORT Metaanalysis Group (1998) Postoperative radiotherapy in non-small cell lung cancer. Lancet 352:257–263CrossRefGoogle Scholar
  37. Präuer HW, Fürst H, Thetter O (2000) Operative Behandlung des Bronchialkarzinoms. In: Schalhorn A (Hrsg) Tumorzentrum München: Empfehlungen zur Diagnostik, Therapie und Nachsorge -Tumoren der Lunge und des Mediastinums. Zuckschwerdt, München, S 42–51Google Scholar
  38. Präuer HW, Schalhorn A, Zimmermann F (2000) Tumoren des Mediastinums: Diagnostik und Therapie. In Schalhorn A (Hrsg) Manual Tumoren der Lunge und des Mediastinums, 5. Aufl. Zuckschwerdt, München, S 121–129Google Scholar
  39. Rodriguez J, Pawel J, Pluzanska A et al. (2001) A multicenter, randomized phase III study of docetaxel + cisplatin and docetaxel + carboplatin vs. vinorelbine + cisplatin in chemotherapynaive patients with advanced and metastatic non-small cell lung cancer. ASCO Proc 20:141, 1252Google Scholar
  40. Ruffie P, Feld R, Minkin S et al. (1989) Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study off 332 patients. J Clin Oncol 7:1157–1168PubMedGoogle Scholar
  41. Scagliotti GV, De Marinis F, Rinaldi M et al. (2000) Phase III randomized trial comparing three platinum based doublets in advanced non-small cell lung cancer. ASCO Proc 20:308a, 1227Google Scholar
  42. Schalhorn A (1985) Bronchialkarzinom: Möglichkeiten und Grenzen der Chemotherapie.Teil I: Kleinzelliges Bronchialkarzinom.Teil II: Nicht-kleinzelliges Bronchialkarzinom. Fortschr Med 103: 309–311, 453–456PubMedGoogle Scholar
  43. Schalhorn A (2000) Chemotherapie des kleinzelligen Bronchialkarzinoms. In: Schalhorn A (Hrsg) ManuakTumoren der Lunge und des Mediastinums, 5. Aufl. Zuckschwerdt, München, S 121–129Google Scholar
  44. Schalhorn A (2002) Moderne Chemotherapie beim Bronchialkarzinom. Internist 43:416–430PubMedCrossRefGoogle Scholar
  45. Schalhorn A, Sunder-Plassmann L (2000) Bronchialkarzinom. In: Wilmanns W, Huhn D, Wilms K (Hrsg) Internistische Onkologie. Thieme, Stuttgarts 617–640Google Scholar
  46. Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. New Engl J Med 346:92–98PubMedCrossRefGoogle Scholar
  47. Seeber S, Niederle N (1983) Chemotherapie des kleinzelligen Bronchialkarzinoms. In: Hellriegel KP, Sack H (Hrsg) Bronchialkarzinom, Mammakarzinom. Springer, Berlin Heidelberg New York Tokyo, S11–18Google Scholar
  48. Shepherd FA, Dancey J, Ramlau R et al. (2000) Prospective randomized trial of docetaxel vs. supportive care in patients with non-small-cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol 18:2095–2103PubMedGoogle Scholar
  49. Sobin LH, Wittekind C (eds) (1997) TNM: Classification of malignant tumours, 5th edn.Wiley-Liss, New YorkGoogle Scholar
  50. Strauss MJ, Moran RE, Shakney SE (1983) Growth characteristics of lung cancer. In: Srauss MJ (ed) Lung cancer.Clinical diagnosis and treatment. Grune&Stratton, New York, pp 63–84Google Scholar
  51. The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • A. Schalhorn
  • R. M. Huber

There are no affiliations available

Personalised recommendations